Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.

Summary

This is a multicenter, open-label phase I/II study, divided into 2 parts: Part 1 involves a dose-escalation study of ZG006 in which the safety and tolerability of ZG006 in patients with advanced small cell lung cancer or neuroendocrine carcinoma are explored. Upon completion of Part 1, investigators and the sponsor will discuss and determine two recommended phase II doses (RP2D) based on safety, preliminary efficacy, and pharmacokinetic results for use in Part 2. Part 2 is a phase II dose-expansion study of ZG006, aiming to investigate the efficacy and safety of ZG006 in patients with Neuroendocrine Carcinoma.

Eligibility

Inclusion Criteria:

* Fully understand the study and voluntarily sign the informed consent form;
* Male or female 18\~75 years of age;
* Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1;
* Life expectancy ≥ 3 months.

Exclusion Criteria:

* Participants were deemed unsuitable for participating in the study by the investigator for any reason.

Conditions3

Interventions1

Related trials

• Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer — Suzhou Zelgen Biopharmaceuticals Co.,Ltd
• Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer — Suzhou Zelgen Biopharmaceuticals Co.,Ltd
• Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer — Suzhou Zelgen Biopharmaceuticals Co.,Ltd
• Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma — Suzhou Zelgen Biopharmaceuticals Co.,Ltd
• Study of ZGGS34 in Participants With Advanced Solid Tumors — Suzhou Zelgen Biopharmaceuticals Co.,Ltd
• ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma — Suzhou Zelgen Biopharmaceuticals Co.,Ltd
• A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer — Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Browse More Trials